No way BP prices 50% more for Rest of the world where Amarin has to sell the rights to others and only collect a small percentage in residual. Europe accounted for less than 15% of overall sales for best selling statin without having to be a residual, no way Amarin gets more than 10-15% from a BP for ROW.
I believe that note is unrelated to BO, that note is related to GIA revenue not model for BO In think.
$40 is the low and $55 is high per share in any BO scenario int he next 6 months.